Factors that negatively affect the prognosis of pediatric community-acquired pneumonia in district hospital in Tanzania by Caggiano, S. et al.
 International Journal of 
Molecular Sciences
Article
Factors That Negatively Affect the Prognosis of
Pediatric Community-Acquired Pneumonia in
District Hospital in Tanzania
Serena Caggiano 1,2,*, Nicola Ullmann 1, Elisa De Vitis 3, Marzia Trivelli 2, Chiara Mariani 2,
Maria Podagrosi 2, Fabiana Ursitti 2, Chiara Bertolaso 2, Carolina Putotto 2, Marta Unolt 2,
Andrea Pietravalle 2, Paola Pansa 2, Kajoro Mphayokulela 4, Maria Incoronata Lemmo 4,
Michael Mkwambe 4, Joseph Kazaura 4, Marzia Duse 2, Francesco Nieddu 3, Chiara Azzari 3
and Renato Cutrera 1
1 Respiratory Unit, Bambino Gesù Children’s Hospital, 00165 Rome, Italy; nicola.ullmann@opbg.net (N.U.);
renato.cutrera@opbg.net (R.C.)
2 Department of Pediatrics, Sapienza University of Rome, Umberto I Hospital, 00161 Rome, Italy;
marzia.trivelli@gmail.com (M.T.); chiaramariani23@yahoo.it (C.M.); maripod@hotmail.com (M.P.);
fabianaursitti@gmail.com (F.U.); chiara.bertolaso@hotmail.it (C.B.); caro_85@hotmail.it (C.P.);
marta_unolt@hotmail.it (M.U.); apietravalle@gmail.com (A.P.); pansa.paola@gmail.com (P.P.);
marzia.duse@gmail.com (M.D.)
3 Department of Clinical Immunology, University of Florence and Children’s University Hospital A. Meyer,
50139 Florence, Italy; ely87_dv@hotmail.it (E.D.V.); francesco.nieddu@meyer.it (F.N.);
chiara.azzari@unifi.it (C.A.)
4 Pediatric Unit, St. Gaspar Hospital, Box 12, Itigi, Tanzania; akajoroa@yahoo.com (K.M.);
waursulitigi@yahoo.it (M.I.L.); mikaelimkwambe@rocketmail.com (M.M.); sereka@hotmail.it (J.K.)
* Correspondence: serena.caggiano@opbg.net; Tel.: +39-06-6859-2020
Academic Editors: Susanna Esposito and Francesco B. Blasi
Received: 6 December 2016; Accepted: 17 February 2017; Published: 13 March 2017
Abstract: Community-acquired pneumonia (CAP) is still the most important cause of death in
countries with scarce resources. All children (33 months ± 35 DS) discharged from the Pediatric
Unit of Itigi Hospital, Tanzania, with a diagnosis of CAP from August 2014 to April 2015 were
enrolled. Clinical data were gathered. Dried blood spot (DBS) samples for quantitative real-time
polymerase chain reaction (PCR) for bacterial detection were collected in all 100 children included.
Twenty-four percent of patients were identified with severe CAP and 11% died. Surprisingly, 54%
of patients were admitted with a wrong diagnosis, which increased complications, the need for
antibiotics and chest X-rays, and the length of hospitalization. Comorbidity, found in 32% of children,
significantly increased severity, complications, deaths, need for chest X-rays, and oxygen therapy.
Malnourished children (29%) required more antibiotics. Microbiologically, Streptococcus pneumonia
(S. p.), Haemophilus influenza type b (Hib) and Staphylococcus aureus (S. a.) were the bacteria more
frequently isolated. Seventy-five percent of patients had mono-infection. Etiology was not correlated
with severity, complications, deaths, oxygen demand, or duration of hospitalization. Our study
highlights that difficult diagnoses and comorbidities negatively affect clinical evolution. S. p. and Hib
still play a large role; thus, implementation of current vaccine strategies is needed. DBS is a simple
and efficient diagnostic method for bacterial identification in countries with scarce resources.
Keywords: community-acquired pneumonia; developing countries; prevention; vaccines; molecular
diagnostic; antibiotic therapy
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1. Introduction
Pneumonia is a major cause of morbidity and mortality in children and adults in low and
middle-income countries [1]. Pneumonia kills an estimated 1 million children under the age
of 5 every year and accounts for 15% of deaths in preschool children, [2] with around 90% occurring
in the developing world [3,4]. In low-income countries, access to medical care is often difficult and
the availability of anti-microbial therapy, of routine vaccination, and of supportive treatment such as
nutrition and oxygen supplementation is still scarce [5]. Of the 6.3 million children who died in their
first 5 years of life in 2013 worldwide, 52% died of infectious disease, and pneumonia was responsible
for at least 15% of total deaths [6]. The main risk factors for community-acquired pneumonia (CAP)
include age (<1 year), malnutrition, lack of breast feeding, prematurity, immunosuppression, HIV
infection, overcrowding, passive tobacco exposure, exposure to indoor air pollution, and the winter
season [7,8]. Co-existing illnesses, such as malaria and diarrhea, are also important contributing
factors to the increased CAP burden of disease in underdeveloped countries [9]. Because of the limited
access to health care in terms of microbiological and radiological investigation, clinical symptoms are
often essential to make diagnoses of pneumonia and to guide empiric treatment in countries with
limited resources. For instance, tachypnea alone is considered an indication to start treatment in a
child with a cough in an ambulatory setting; however, when signs of respiratory distress are present,
hospitalization is suggested [10]. WHO recommends a diagnostic algorithm that takes into account
clinical signs such as age-specific respiratory rates, lower chest indrawing, and several key danger signs
such as cyanosis and the inability to feed [11]. An accurate etiologic diagnosis is often complicated and
differentiating between bacterial and nonbacterial pneumonia is clinically difficult. Current evidence
suggests severe pneumonia results from infection with multiple pathogens such as bacterial-viral,
dual viral, or mycobacterial bacterial infections [1]. It has been reported that up to a third of children
with pneumonia may have viral-bacterial co-infections [12]. Streptococcus pneumoniae (S. p.) and
Haemophilus influenza type b (Hib) are the two principal causes of bacterial infection. These pathogens
can be prevented by immunization or treated with low-cost antibiotics, but it has been estimated that
only 30% of children with bacterial pneumonia receive the correct treatment. S. p. causes up to 18%
of severe cases and 33% of deaths [13], followed by Hib (4% of severe episodes and 16% of deaths),
and, finally, by influenza virus (7% of severe episodes and 11% of deaths). Other pathogens frequently
identified are Staphylococcus aureus (S. a.), Klebsiella pneumoniae (K. p.), and Mycobacterium tuberculosis
(M. t.) in endemic areas. According to diagnostic tools, it is known that chest X-rays are often unable to
differentiate bacterial from viral infections because of similar radiographical findings [14], and a clinical
presentation has low specificity and sensitivity. With these assumptions, microbiological confirmation
seems to be essential for accurate diagnosis [5] and useful for selecting the most appropriate treatment.
Among microbiological techniques, on one side, the high prevalence of nasopharyngeal colonization
by potentially pathogenic bacteria limits the use of respiratory samples; on the other side, blood culture
has the disadvantage of offering results after 24–48 h, and it is often impaired by pre-treatment with
antibiotics. Other molecular techniques such as blood PCR (polymerase chain reaction) assays have
the benefit of reducing these short comings and of identifying pneumonia etiology quickly. Dried
blood spot (DBS) sampling is a simple method that does not need very large volumes of any given
sample, which is essential for any pediatric test and screening of large populations, especially in
countries where healthcare facilities are not readily accessible [15]. DBS has been described as easily
transportable and able to identify and serotype S. p. at room temperature [16].
The WHO estimates that 1.5 million children continue to die every year from vaccine-preventable
diseases, accounting for 17% of all under-5 deaths [17]. Particularly, S. p. and Hib are considered to be
the leading cause of child pneumonia deaths worldwide and a universal use of conjugated Hib and
pneumococcal vaccines should prevent approximately 1 million child deaths per year [18–20]. Delayed
introduction of conjugated vaccines in developing countries is mostly attributed to high cost and lack
of political will, resulting in widening vaccine schedule gaps between developed and under developed
countries. While some preventable risk factors for severe lung infectious disease in developing
countries have been hypothesized, the literature is still scarce on the characterization of clinical
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presentation, prognosis, and the microbiological definition of pediatric pneumonia in low-income
countries [21]. The main purpose of our prospective study was to analyze a large population of
children hospitalized with CAP in a country with limited resources and identify the principle factors
that negatively affect clinical evolution. Moreover, we planned to explore infection etiology by the use
of reproducible DBS samples from pediatric patients and correlate results with clinical characteristics.
2. Results
2.1. Patients
Through our prospective study, we consecutively enrolled 100 children (mean age 33 months ± 35 DS)
dismissed from Itigi hospital in Tanzania with a diagnosis of pneumonia. Forty-seven percent were
boys, and 36% were infants (<12 months). Twenty-nine percent were classified as malnourished,
identifying malnutrition in a weight for age Z-score ≤ 2. The average length of hospitalization
was 10 ± 6 days. Twenty-four percent of patients were identified with severe pneumonia, and 11%
of all children died. Demographics and clinical characteristics of the study population are clearly
described and summarized in Table 1.
Table 1. Demographics and clinical characteristics of the study population.
Background Characteristics (n = 100 Patients) (%)
Median age in months 33 ± 35
0–6 months 21
7–11 months 15
12–48 months 43
49–144 months 21
Boys 47
Underweight (weigh for age Z-score < −2) 29
Clinical Characteristics
Fever 96
Cough 97
Tachypnea 35
Chest indrawing 27
Crackles 99
Decreased breath sounds 49
Hypoxia (SpO2 < 90%) 19
Wheezing 27
Pleural effusion or empyema 9
Severe pneumonia 24
Death 11
Hospitalization
Admitting diagnosis different from pneumonia 53
Length of stay (day) 10 ± 6
Oxygen therapy 19
Chest X-ray 25
≥2 antibiotics 88
Comorbidities (n = 32 Patients) 32
Malaria 28
Typhoid fever 16
Anemia 13
Meningitis 6
Herbal poisoning 6
Osteomyelitis 6
Measles 6
Nephrotic syndrome 6
Rheumatic heart disease 6
Tuberculosis 6
Urinary tract infection 6
Down syndrome 6
Laryngospasm 6
Bowel obstruction 6
Head injury 6
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2.2. Comorbidities
Co-morbidities were present in 32% of patients with malaria as the most common condition,
followed by typhoid fever and anemia (Table 1). Co-morbidities significantly increased the severity of
pneumonia, including the need for oxygen and the number of deaths, and co-morbidities were
significantly associated with more complications and the need for chest radiographs (p < 0.05).
Comorbidities did not increase the length of hospitalization. Furthermore, we observed more
antibiotics administered in patients without comorbidities (p < 0.05).
2.3. Initial Diagnosis Different from Pneumonia
Surprisingly, in more than half of the hospitalized patients, pneumonia was not originally
recognized at the first evaluation in the emergency department when admission was decided.
The incorrect diagnosis at admission significantly increased the frequency of complications,
the need for ≥2 antibiotics, and radiological investigations (p < 0.05). Patients with an initial wrong
diagnosis did not experience more oxygen demand or a higher number of deaths. As expected though,
initial misdiagnosis increased the length of hospitalization by two days.
2.4. Malnutrition
Children with malnutrition required more antibiotic treatment (p < 0.05), but they did not show
significant differences from other patients in terms of severity, deaths, comorbidities, or the need for
medical intervention and length of stay.
2.5. Wheezing
Wheezing was diagnosed in 27% of children. These patients had increased severity of pneumonia
(p < 0.01) and incremented a need for supplemental oxygen therapy (p < 0.05).
2.6. Bacterial Infections
Table 2 describes the main microbiological findings. In 52 (62%) patients, S. p. was isolated;
Hi was detected in 23 patients (27%), mainly Hib, as was S. a. in 17 of our cases (20%).
Five children had Pseudomonas aeruginosa (P. a.) (6%), and in 3 patients (3%), Salmonella typhi
(S. t.) was detected. Seventy-five percent of patients had mono-infection, and the remaining 25%
showed bacterial co-infection, by far most frequently between S. p. and Hi (57%), followed by S. p. and
S. a. (14%), Hi and S. a. (14%), Hi + S. t. (9.5%), and S. p. + P. a. (5%). Patients with pneumococcical
etiology showed apparently milder pneumonia (p < 0.05), and pneumococcal bacterium was not
isolated more frequently in patients with comorbidities. Neither S. p. nor Hi, nor even S. a., in
mono-infection was most frequently isolated in malnourished or younger children. Moreover, none of
these bacteria was associated with more severe pneumonia, the occurrence of complications, or death.
Furthermore, subjects with mono-infection did not have more oxygen demand, nor did they require
more chest-X rays or longer hospital admission. Interestingly, children with Hi infection presented less
wheezing (p < 0.05). Finally, S. p. and Hi in coinfection were not associated with more disease severity,
number of complications, days of hospitalization, or a need for chest X-rays and oxygen therapy,
but this coinfection was find more frequently in children with comorbidities (p < 0.01).
2.7. Need for Oxygen
As expected, the need for oxygen was significantly associated with a clinical diagnosis of severe
pneumonia and increased in patients with negative prognosis (p < 0.05).
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Table 2. Description of microbiological findings.
Microbiology Findings Real-Time PCR on Dried
Blood Spot Sample (n = 100 Patients) (%)
Negative 16
Monoinfection 63
Coinfection 21
Streptococcus pneumoniae 52
Haemophilus influenzae 23
H. influenzae type b 17
Staphylococcus aureus 17
Pseudomonas aeruginosa 5
Salmonella typhi 3
Coinfection
Streptococcus pneumoniae + Haemophilus influenzae 12
Streptococcus pneumoniae + Staphylococcus aureus 3
Haemophilus influenzae + Staphylococcus aureus 3
Haemophilus influenzae + Salmonella typhi 2
Streptococcus pneumoniae + Pseudomonas aeruginosa 1
2.8. Age
Interestingly, it was observed that a wrong diagnosis was more common in children >36 months
(p < 0.05). Furthermore, we observed that 73% of children who died were malnourished, and those
who were not underweight were younger (≤36 months old).
2.9. Length of Hospitalization
The average length of hospitalization was 10 ± 6 days. In patients with severe pneumonia who
showed a significant increase in deaths (p < 0.05), we observed a shorter length of stay. They died
within the first 8 days of hospitalization.
3. Discussion
Pneumonia is the single biggest killer of children worldwide. We described clinical and
microbiological findings in children that were dismissed with a diagnosis of pneumonia during
the 9-month study period (which included rainy and dry seasons with no difference among them)
in the Pediatric Unit of a Tanzanian hospital. To our knowledge, few previous studies have focused
only on death and hypoxia as main outcomes, while we tried to identify the principle factors that
negatively affect the clinical evolution of children hospitalized with CAP in a country with limited
resources. Moreover, we planned to explore infection etiology by the use of reproducible DBS
samples from pediatric patients and correlate results with clinical characteristics. We looked for those
factors correlating with severe pneumonia, deaths, complications, a need for oxygen and more use of
antibiotics, as well as a need for chest X-rays and a certain length of stay, among other epidemiologic
factors such as age, gender, weight for age, clinical symptoms, comorbidity, and microbiological
outcomes. Our data showed that co-morbidity, a need for supplemental oxygen, and clinical diagnosis
of severe pneumonia were correlated to increased mortality among patients hospitalized with CAP.
Interestingly, patients with severe pneumonia showed a significantly shorter length of stay because
death occurred within the first eight days. This data could be explained by the absence of a pediatric
intensive care unit with impossibility for patients to receive intensive treatment when needed. No
differences among genders and age were observed in terms of death and severity of pneumonia,
but misdiagnosis was more frequent in children ≥3 years old with the direct consequence of longer
hospitalization. From our population, 73% patients that died were malnourished, and the rest of
the deaths occurred in young children (≤36 months old), possibly indicating that any of the factors
facilitated a negative exitus. Unexpectedly, more than half of the patients had been hospitalized with a
suspected diagnosis other than CAP, and the wrong diagnosis at admission increased both radiological
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examinations and antibiotic therapy. In rural Africa, at the moment, most hospital visits and admissions
are attended only by nurses or paramedics, and diagnoses or management decisions can only be guided
by clinical signs and symptoms [22]. As is known, the specificity of a clinical presentation of CAP
is poor, and the diagnosis can be often difficult or uncertain, particularly with limited diagnostic
resources. It is known that overlap between different diseases such as pneumonia and malaria, the
most frequent comorbidity in our population, is possible. Infection such as malaria may predispose one
to acquire bacterial infection but also may clinically mimic severe pneumonia. However, malaria, as a
comorbidity, did not determine the worst clinical trend of CAP. A complete training of all professional
figures in charge of medical care and a deep comprehension of the interaction of different diseases
are essential to improving correct diagnosis and treatment [23]. Gastroenteritis and dehydration are
reported as common comorbidities that may predispose one to pneumonia [24]. In our population
though, we described many other different comorbidities such as typhoid fever, measles, or clinical
conditions determined by local herbs intoxication. The presence of these diseases is to be related
to poor adherence to international vaccination programs and to the popularity of dangerous local
traditions. We reported an increase in antibiotics administration to patients with isolated pneumonia
without comorbidities, which can be explained by a quicker diagnostic classification and the immediate
prescription of a broad-spectrum antibiotic. In resource-limited settings, chest X-rays are rarely used
to guide clinical management of severe pneumonia [21]. However, in the case of a wrong initial
assessment or clinical conditions complicated by the presence of comorbidities, a chest radiograph
confirmed its utility in a differential diagnosis in difficult settings. Hypoxemia was shown to be
a predictor of poor outcome, as reported from other studies [22]. As expected, low blood oxygen
saturation was shown to be significantly linked to severe pneumonia and death [25,26]; moreover,
the need for oxygen was increased in the presence of comorbidity and wheezing. The latter was
diagnosed in a quarter of patients, especially in children with severe pneumonia, but it did not appear
to be related to any specific microorganism. We speculate that the viral nature of some of these
infections might have triggered wheezing symptoms. It is known that impaired children’s growth
and underlying malnutrition is a major risk factor for pneumonia [27], and this is supported by our
result of increased and multiple antibiotic therapy used for children with a <−2 Z-score. However,
in our population, malnutrition, described in around 25% of patients, did not show any significant
correlation with other outcomes. Our data confirmed that S. p., Hib, and S. a. are the main bacteria
causing pneumonia. A recent study from Gambia involving children younger than 5 years with
severe pneumonia demonstrated S. p. to be present in 91% of lung aspirates, followed by Hi at
23%, and S. a. in 6% [27]. Besides poor prevention, which can explain the bacterial etiology for all
children in limited resources countries, Gram-negative bacteria have been shown to be more common
in children with malnutrition [28]. In fact, Hi was the most common non-pneumococcal pathogen
isolate in our study. In the literature, the role of non-pneumococcal pathogens is described as an
independent predictor of mortality [29]. Our study described that non-pneumococcal infections were
significantly correlated with severe pneumonia possibly because those patients had also compromised
a general condition, were undernourished, and had more comorbidities. The same significant increase
in comorbidities were observed in cases of coinfection between Hi and S. p., probably because it is more
susceptible to these bacteria. Finally, we could not identify any specific bacteria as a negative predictive
factor of death. As confirmed by our study, dried blood spot (DBS) sampling is a useful and easy
method for preserving and transporting blood samples. This is particularly important in developing
countries where health services are not easily accessible and microbiology laboratories are rare with
limited technical expertise. DBS collection can overcome the obstacles associated with the collection
and storage of biological samples. DBS may be suitable for the detection of infectious pathogens
by real-time PCR (RT-PCR) [15]. RT-PCR, as is known, is a sensitive and specific method, which
allows for the detection of a great number of pathogens. Therefore, DBS sampling can be used for
pathogen detection and allow for diagnosis. The results of our study of a large population of African
children contribute towards a better understanding of the main etiological causes of pneumonia
in low-income countries. Our paper together with the final results of a few ongoing studies will
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provide more updated and comprehensive data regarding pneumonia in children living in low-
and middle-income countries [30,31]. Our data highlight poor adherence to Hib and pneumococcal
conjugate vaccines. Currently used conjugate vaccines worldwide include the 13-valent conjugate
vaccines (pneumococcal conjugate vaccine 13 (PCV13)) that have shown a substantial positive impact
on the burden of pneumococcal disease. The positive effects are expected to be even more dramatic
among young children in low- and middle-income countries [32]. A meta-analysis of serotypes causing
CAP worldwide estimated that 49% to 88% of pneumococcal deaths in Africa and Asia are caused
by serotypes covered in in PCV10 and PCV13 [33]. Since 2006, the WHO has recommended that
PCV and Hib conjugate vaccines be included in all routine immunization programs. However, the
uptake of PCV in low- and middle-income countries has been limited, in large part because of a
vaccine’s elevated cost. The Global Alliance for Vaccines and Immunization (GAVI) has worked hard
to accelerate the diffusion of PCV10 and PCV13 vaccines in developing countries, ensuring more
affordable prices. Currently, more than 190 countries have introduced a Hib-containing vaccine into
their national immunization program [34]. In Tanzania, the Expanded Programme on Immunization
in order to reduce morbidity and mortality caused by preventable infections in children under 5 years
of life started in 1975. However, in the Itigi district, where our study took place, the vaccinations
for Hib and pneumococcal conjugate vaccine 13-valent were introduced from 2012, administering
vaccines among small villages in order to make vaccinations available to all. Our results, though, still
confirm a high prevalence of S. p. and Hi infections in children admitted for pneumonia; therefore,
our study stresses the need for a global campaign to significantly improve the adherence to the local
immunization programme.
We recognize certain limits to our research study: the laboratory test could not detect viral and
fungal infections; however, considering the low prevalence of microbiological negative results, we can
assume that results would not be significantly different. Moreover, we could not include HIV detection
because of local healthcare organization and resources.
4. Materials and Methods
4.1. Patients
In this prospective study, we consecutively enrolled all children discharged with a diagnosis of
community-acquired pneumonia from Pediatric Unit of St. Gaspar Hospital in Itigi, a rural village
in Tanzania, from August 2014 to April 2015. Pneumonia was defined using WHO guidelines [11].
We classified pneumonia as severe or non-severe on the basis of clinical features, being the management
based on the classification. Clinical data until discharge were gathered and analyzed.
4.2. Definitions
According to WHO classification [11], we defined pneumonia as characterized by the following:
• fast breathing—≥50 breaths/min in a child aged 2–11 months and ≥40 breaths/min in a child
aged 1–5 years;
• lower chest indrawing;
• chest auscultation suggestive of crackles, pleural rub, bronchial breath sounds, and/or abnormal
vocal resonance.
Severe pneumonia defined as difficulty in breathing or cough associated with at least one of
the following:
• oxygen saturation <90% registered with pulse oximetry or central cyanosis;
• severe respiratory distress;
• signs of general impairment such as convulsions, lethargy, unconsciousness, or inability to feed;
• one or more signs of pneumonia.
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4.3. Treatment
Initial treatment for pneumonia was represented by oral amoxicillin, 40 mg/kg per dose twice a
day for 5 days.
Patients with severe pneumonia were administrated intravenous ampicillin (or benzylpenicillin)
and gentamicin. Ampicillin 50 mg/kg or benzylpenicillin 50,000 U/kg IM or IV every 6 h for at least
5 days. Gentamicin 7.5 mg/kg IM or IV once a day for at least 5 days. Ceftriaxone (80 mg/kg IM or IV
once daily) was used in cases of failure of first line treatment.
When staphylococcal pneumonia was suspected: cloxacillin (50 mg/kg IM or IV every 6 h) or
another antistaphylococcal antibiotic, such as oxacillin, flucloxacillin, or dicloxacillin and gentamicin
(7.5 mg/kg IM or IV once a day) were prescribed.
Oxygen was given for levels of oxygen saturation <90% and fluids per os or intravenously were
prescribed to guarantee appropriate hydration.
4.4. Investigations
All patients underwent a triage assessment with clinical general evaluation in the Emergency
Unit and received an initial suspected diagnosis before admission was decided. In the pediatric ward,
they received a new clinical evaluation. Oxygen saturation was measured with pulse oximetry in
all children and blood samples taken. Blood cultures were reserved only on cerebrospinal fluid in
suspected meningitis. When clinically indicated, a chest X-ray was performed.
Weight for-age Z-score was calculated using the 2006 WHO Child Growth Standards. Malnutrition
was defined when these parameter was below −2 Z-score.
Drops of blood of each patient were collected on filter paper.
We used 4 punches of each sample and the DNA extraction was processed using a MagCore®
Automated Nucleid Acid Extractor and following MagCore® Nucleid Acid Tissue Extraction Kit
Protocol (Company Diatech Lab Line, Ancona, Italy). The eluate volume was 60 uL. Real-time PCR
on DBS made for detecting at the beginning S. p., Hi, Neisseria meningitidis, Pneumocistis jirovecii, S. a.,
S. p. and other bacterial microorganism present in the sample, like P. a., Klebsiella pneumoniae, and S. t.
When we had a positive sample for S. p. or Hi detection, we proceeded with serotyping. Diagnosis of
laboratory-confirmed bacteremic pneumonia was performed in the presence of positive RT-PCR for
target gene, like lytA for S. p. or ctrA for Neisseria meningitides. The cycle threshold (Ct) value is the
PCR cycle number (of 45) at which the measured fluorescent signal exceeds as calculated background
threshold, identifying the amplification of target sequence. The sample was assumed negative if there
was no increase in fluorescent signal before the 40th cycle. The serotyping of S. p. by RT-PCR was
performed using 36 different primers/probes, which were devised in a different region of the CpsA
gene. We included PCV-13 serotypes and non-vaccine serotypes, according to Hsu et al [35].
4.5. Ethics Statement
The study, identification code SG012014, was approved on 30 July 2014 by the St. Gaspar Medical
Centre Research Ethics Committee, Singida, Manyoni district, Tanzania. Informed consent was
obtained for eligible children from parents or guardians.
4.6. Statistical Analysis
Data are expressed as a mean standard deviation. Analysis was performed using Epi Info
version 3.01 (CDC, Atlanta, GA, USA). Categorical data were compared using χ2 test or Fisher’s
test, respectively, if all expected values were <5 or ≥5. A p-value < 0.05 was considered significant.
The Student’s t-test was used to compare mean values of normally distributed quantitative variables.
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5. Conclusions
Our study confirms that pneumonia, often with the presence of comorbidities, continues to be one
of the leading killers of young children in poor developing countries. Malnutrition and young age are
still dangerous factors that predispose children to death. Considering the high prevalence of wrong
diagnosis at admission, a complete training programme of all health workers and a standardization
of treatments to guarantee the best diagnostic and therapeutic approaches is needed. Direct positive
consequences include a significant reduction of disease complications and a reduction in the use
of scarce healthcare resources. Moreover, we reported that the majority of severe pneumonia and
deaths are still caused by S. p. and Hi. despite the actual vaccination program. More effort is
therefore needed to prevent infections, to improve adherence to available vaccines, and to implement
pathogen-specific vaccines into the national immunization programs. In this setting, improving the
etiological surveillance of pneumonia with simple techniques such as real-time PCR from blood spots
may have critical implications for prevention and treatment policies. Finally, our data still sadly
confirms the discrepancies between health assistance among developed and developing countries.
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Abbreviations
CAP Community-acquired pneumonia
DBS Dried blood spot
PCR Polymerase chain reaction
RT-PCR Real-time polymerase chain reaction
HIV Human immunodeficiency virus
PCV13 Pneumococcal conjugate vaccine 13
S. p. Streptococcus pneumoniae
Hi Haemphilus influenza
Hib Haemophilus influenza type b
S. a. Staphilococcus aureus
P. a. Psedomonas aeruginosa
S. t. Salmonella typhi
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